Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 12/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101807 | 0.91 | NPC1 (0.38) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101808 | 0.91 | RAB9A (0.41) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101819 | 0.90 | PPARG (0.42) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101805 | 0.89 | S1PR1 (0.37) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101793 | 0.87 | NPC1 (0.37) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101794 | 0.85 | S1PR1 (0.46) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101812 | 0.85 | NPC1 (0.37) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101816 | 0.84 | S1PR1 (0.47) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10102289 | 0.82 | RAB9A (0.46) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101815 | 0.81 | L3MBTL1 (0.53) | S1PR1NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | S1PR1 909/4885S1PR3 881/4885NPC1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.